Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Choroideremia: early-phase trial registry
3 of 8 indexed Choroideremia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 3 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Choroideremia: 8 US clinical trials tracked, 3 recruiting.
Choroideremia is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Ray Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition choroideremia
OPEN 3 | RECR 38% | LATE 0 | EARLY 4 | RANK #2176 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute-graft-versus-host Disease (38% recruiting · 8 trials)
Choroideremia lists 3 open slots (38% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Choroideremia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Choroideremia is recruiting below its size-band peers.
3 of 8 indexed trials (37.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Choroideremia research.
Ray Therapeutics accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Choroideremia enrolment sits around 120 participants.
Median target enrolment is 120 among the 8 trials that report a genuine target (sentinel values excluded). 4 of those (50%) plan for fewer than 100 participants.
-
Choroideremia splits between interventional and observational designs.
4 interventional and 4 observational studies make up this index (50% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
Inherited Retinal Degenerative Disease Registry
Foundation Fighting Blindness
NCT02435940
High Resolution Retinal Imaging
University of Pennsylvania
NCT01866371
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
Ray Therapeutics
NCT06375239
Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia
4D Molecular Therapeutics
NCT04483440
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
Ray Therapeutics
NCT06460844
Natural Disease Progression in Participants With Choroideremia
Biogen
NCT04795206
Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations
Spark Therapeutics
NCT02341807
Choroideremia Gene Therapy Clinical Trial
Byron Lam
NCT02553135
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Choroideremia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Choroideremia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Choroideremia page
8 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Choroideremia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Ray Therapeutics sponsors the most Choroideremia trials on record, review their full trial history before evaluating a specific study. See Ray Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Choroideremia condition card totals 8 registered trials; most-linked intervention Injection of AAV2-REP1 (10e11 vg); top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.